AU2015209761B2 - Benzoxazinone derivatives for treatment of skin diseases - Google Patents

Benzoxazinone derivatives for treatment of skin diseases Download PDF

Info

Publication number
AU2015209761B2
AU2015209761B2 AU2015209761A AU2015209761A AU2015209761B2 AU 2015209761 B2 AU2015209761 B2 AU 2015209761B2 AU 2015209761 A AU2015209761 A AU 2015209761A AU 2015209761 A AU2015209761 A AU 2015209761A AU 2015209761 B2 AU2015209761 B2 AU 2015209761B2
Authority
AU
Australia
Prior art keywords
treatment
klk7
skin
compound
skin disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015209761A
Other languages
English (en)
Other versions
AU2015209761A1 (en
Inventor
Goran Leonardsson
Fredrik Wagberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sixera Pharma AB
Original Assignee
Sixera Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sixera Pharma AB filed Critical Sixera Pharma AB
Publication of AU2015209761A1 publication Critical patent/AU2015209761A1/en
Application granted granted Critical
Publication of AU2015209761B2 publication Critical patent/AU2015209761B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2015209761A 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases Active AU2015209761B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1430003-2 2014-01-23
SE1430003 2014-01-23
PCT/SE2015/050062 WO2015112081A1 (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases

Publications (2)

Publication Number Publication Date
AU2015209761A1 AU2015209761A1 (en) 2016-07-07
AU2015209761B2 true AU2015209761B2 (en) 2018-11-29

Family

ID=53681747

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015209761A Active AU2015209761B2 (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases

Country Status (18)

Country Link
US (2) US9695194B2 (enExample)
EP (1) EP3097085B1 (enExample)
JP (1) JP6448651B2 (enExample)
CN (1) CN106132941B (enExample)
AU (1) AU2015209761B2 (enExample)
CA (1) CA2934025C (enExample)
CY (1) CY1123477T1 (enExample)
DK (1) DK3097085T3 (enExample)
ES (1) ES2820868T3 (enExample)
HR (1) HRP20201500T1 (enExample)
HU (1) HUE051296T2 (enExample)
LT (1) LT3097085T (enExample)
PL (1) PL3097085T3 (enExample)
PT (1) PT3097085T (enExample)
RS (1) RS60830B1 (enExample)
SI (1) SI3097085T1 (enExample)
SM (1) SMT202000557T1 (enExample)
WO (1) WO2015112081A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3097085T3 (da) * 2014-01-23 2020-10-26 Sixera Pharma Ab Benzoxazinonderivater til behandling af hudsygdomme
BR112017020977B1 (pt) 2015-05-13 2021-03-30 Nihon Nohyaku Co., Ltd Composto de éster de ácido antranílico ou seu sal, microbicidas agrícolas e hortícolas que compreendem o composto, e método para usar o microbicida
EP3402572B1 (en) * 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
EP4740954A3 (en) 2017-06-16 2026-08-05 Azitra, Inc. Compositions and methods for treatment of netherton syndrome with lekti expressing recombinant microbes
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
US12360103B2 (en) 2018-04-20 2025-07-15 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
GB201809378D0 (en) 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
AU2020349509A1 (en) 2019-09-18 2022-03-31 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
MX2022003929A (es) 2019-10-01 2022-06-14 Molecular Skin Therapeutics Inc Compuestos de benzoxazinona como inhibidores dobles de klk5/7.
GB202001447D0 (en) * 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
BR102020009679A2 (pt) 2020-05-14 2021-11-23 Fundação Universidade Federal Do Abc - Ufabc Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑
CN117396188A (zh) 2021-06-01 2024-01-12 西可斯拉制药公司 6-乙氧基-7-甲氧基-2-(2-甲基硫基苯基)-3,1-苯并噁嗪-4-酮的水包油乳液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108139A2 (en) * 2003-06-06 2004-12-16 Arexis Ab Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB115399A (en) * 1917-03-28 1918-04-29 Reginald Guley Lewis Improved Delivery mechanism for Coin-freed Apparatus and the like.
GB1153994A (en) 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
AU2826099A (en) * 1998-03-24 1999-10-18 Novo Nordisk A/S Heterocyclic compounds regulating clotting
TWI419884B (zh) * 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物
DK3097085T3 (da) * 2014-01-23 2020-10-26 Sixera Pharma Ab Benzoxazinonderivater til behandling af hudsygdomme

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108139A2 (en) * 2003-06-06 2004-12-16 Arexis Ab Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer

Also Published As

Publication number Publication date
CA2934025C (en) 2022-06-07
HUE051296T2 (hu) 2021-03-01
JP6448651B2 (ja) 2019-01-09
US9695194B2 (en) 2017-07-04
ES2820868T3 (es) 2021-04-22
CN106132941A (zh) 2016-11-16
CY1123477T1 (el) 2022-03-24
HRP20201500T1 (hr) 2020-12-25
US20170002021A1 (en) 2017-01-05
LT3097085T (lt) 2020-10-12
EP3097085B1 (en) 2020-07-29
RS60830B1 (sr) 2020-10-30
US20170267692A1 (en) 2017-09-21
EP3097085A1 (en) 2016-11-30
PL3097085T3 (pl) 2021-01-11
EP3097085A4 (en) 2017-08-09
CN106132941B (zh) 2018-04-06
SI3097085T1 (sl) 2020-11-30
WO2015112081A1 (en) 2015-07-30
CA2934025A1 (en) 2015-07-30
PT3097085T (pt) 2020-10-08
JP2017503798A (ja) 2017-02-02
DK3097085T3 (da) 2020-10-26
SMT202000557T1 (it) 2020-11-10
AU2015209761A1 (en) 2016-07-07
US10072024B2 (en) 2018-09-11

Similar Documents

Publication Publication Date Title
US10072024B2 (en) Benzoxazinone derivatives for treatment of skin diseases
Lund et al. Functional overlap between two classes of matrix‐degrading proteases in wound healing
Johnson et al. Matrix metalloproteinases
Swarnakar et al. Matrix metalloproteinases in health and disease: regulation by melatonin
Hersh et al. Neprilysin and amyloid beta peptide degradation
Mittal et al. Intricate functions of matrix metalloproteinases in physiological and pathological conditions
JP6932386B2 (ja) 新しいカリクレイン７阻害剤
Reich et al. Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment
JP2017505299A5 (enExample)
Vincent et al. Regulation of βAPP and PrPc cleavage by α-secretase: mechanistic and therapeutic perspectives
Shin et al. Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9
HK1229792A1 (en) Benzoxazinone derivatives for treatment of skin diseases
HK1229792B (en) Benzoxazinone derivatives for treatment of skin diseases
HK40107125A (en) Activity inhibitor and/or production suppressant
HK1229791B (en) New kallikrein 7 inhibitors
JP2010209055A (ja) 医薬組成物
JP2011168570A (ja) 医薬組成物
HK1229791A1 (en) New kallikrein 7 inhibitors
JP2025105263A (ja) ウロキナーゼとウロキナーゼ受容体の相互作用阻害剤
Sahitya et al. Matrix metalloproteinases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)